^
    23d
    MOMENT: A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Prostate Cancer Clinical Trials Consortium
    New P2 trial
    |
    enzalutamide • abiraterone acetate • mevrometostat (PF-06821497)
    1m
    A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • enzalutamide • abiraterone acetate • mevrometostat (PF-06821497)
    3ms
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=453, Recruiting, Pfizer | Trial completion date: Mar 2029 --> Jul 2029
    Trial completion date
    |
    enzalutamide • Onmel (itraconazole) • Tolsura (SUBA-itraconazole) • mevrometostat (PF-06821497)
    4ms
    C2321008: A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate Cancer Who Have Not Tried Novel Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer (MEVPRO-3) (2024-519369-24-00)
    P2/3, N=434, Recruiting, Pfizer Inc.
    New P2/3 trial
    |
    enzalutamide • mevrometostat (PF-06821497)
    5ms
    MEVPRO-2: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P3, N=900, Recruiting, Pfizer | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    enzalutamide • abiraterone acetate • mevrometostat (PF-06821497)
    5ms
    A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (clinicaltrials.gov)
    P3, N=600, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    docetaxel • enzalutamide • abiraterone acetate • mevrometostat (PF-06821497)
    7ms
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=433, Recruiting, Pfizer | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    enzalutamide • itraconazole • mevrometostat (PF-06821497)
    8ms
    This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (clinicaltrials.gov)
    P3, N=1000, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enzalutamide • mevrometostat (PF-06821497)
    12ms
    This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Pfizer
    New P3 trial
    |
    enzalutamide • mevrometostat (PF-06821497)
    1year
    A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=0, Withdrawn, Pfizer | N=16 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    mevrometostat (PF-06821497)
    1year
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=343, Recruiting, Pfizer | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    enzalutamide • itraconazole • mevrometostat (PF-06821497)
    over1year
    A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Pfizer | Trial completion date: Apr 2025 --> Sep 2025 | Initiation date: Dec 2024 --> Apr 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    mevrometostat (PF-06821497)